• Contact us: info@cagenome.com
-

  • Home
  • Our Company
  • Our Technology
  • Our Research
  • Join us

Research

> Research
Precision AI models

Introducing iGenSig and iGenSig-Rx: Revolutionizing Omics-based Precision Oncology

Genomic Markers

New Biomarker Identified: TAA Burden Could Predict Immunotherapy Success in Cancer Patients Lacking Traditional Markers

Genomic Markers

Intragenic rearrangement burden: Broadening Access to Immunotherapy Through Innovative Genetic Testing

Archives

  • January 2025

Categories

  • Uncategorized
Our proprietary pipeline seamlessly integrates state-of-the-art methodologies in next-generation sequencing (NGS), artificial intelligence (AI), and multi-omic data analytics.
Copyright © 2025 Ca-Genome Rx. All rights reserved.